
Opinion|Videos|January 17, 2025
Time to Progression by Organ with Lenvatinib Plus + Pembrolizumab in Advanced RCC.
Author(s)Viktor Grünwald, MD, PhD, Martin H. Voss, MD
Panelists discuss time to progression by organ with lenvatinib plus + pembrolizumab in advanced renal cell carcinoma (RCC), highlighting key data and its the implications for treatment decisions.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
3
Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC
4
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
5












































































